ILC2-mediated immune crosstalk in chronic (vascular) inflammation

Area of Science:

• Immunology
• Cardiovascular Research
• Inflammation Biology

Background:

• Immune cell crosstalk is essential for immune response and homeostasis.
• Type 2 innate lymphoid cells (ILC2s) regulate tissue homeostasis and repair.
• Inflammation drives atherosclerosis, a key cardiovascular disease (CVD) pathology.

Purpose of the Study:

• To review the atheroprotective role of ILC2s in cardiovascular disease (CVD).
• To explore the mechanisms of chemokine/chemokine receptor signaling in ILC2 function during vascular inflammation.
• To discuss the therapeutic potential of ILC2-mediated immune responses in atherosclerosis.

Main Methods:

• Review of current literature on ILC2s, immune cell interactions, and atherosclerosis.
• Analysis of studies investigating type-II cytokine secretion (IL-5, IL-13, IL-9) by ILC2s.
• Examination of chemokine/chemokine receptor signaling pathways influencing ILC2s in vascular inflammation.

Main Results:

• ILC2s exhibit an atheroprotective role in cardiovascular disease (CVD) through type-II cytokine secretion.
• ILC2s fine-tune innate-adaptive immune cell crosstalk, impacting atherosclerosis progression.
• Chemokine/chemokine receptor signaling significantly shapes ILC2 functions in vascular inflammation.

Conclusions:

• ILC2s represent a promising therapeutic target for cardiovascular disease (CVD) and atherosclerosis.
• Further research into ILC2-immune cell dialogue and chemokine signaling is warranted for novel treatment strategies.
• Harnessing ILC2-mediated protective immune responses could offer future therapeutic avenues for cardiovascular diseases.